Is There a Role for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis Due to Uterine Cancer?
- PMID: 36579503
- PMCID: PMC9693328
- DOI: 10.3390/jpm12111790
Is There a Role for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis Due to Uterine Cancer?
Abstract
Background: Uterine canceris one of the most common pelvic tumors in females. Advanced stage uterine cancer only represents 15% of newly diagnosed cases; however, they are related with poor prognosis. Our aim was to analyze the benefits of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis due to uterine cancer.
Methods: At the Istanbul Umraniye Training and Research Hospital, Surgical Oncology Clinic, morbidity, overall survival and survival without progression were analyzed over the 5-year follow up. Twenty-two cases who had undergone cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to uterine-peritoneal carcinomatosis were included in this study. Cases were followed up in terms of postoperative morbidity-mortality, disease-free survival and overall survival. The cut off value for the peritoneal carcinomatosis index score was set at 15. Intraperitoneal chemotherapy consisting of cisplatin and doxorubicin was applied to all patients for 60 min after the suturation of the abdomen.
Results: Median age of the patients was 64.6 (43-72). Average PCI score was 12.8 (3-15). CC score was 0 in 16 (72.7%) cases, 1 in 3 cases and 2 in 3 cases. Of these patients, 12 of them were previously operated upon. Median stay at the hospital was 13.1 days. No major complications due to chemotherapy were reported. A Clavien-Dindo Grade 3 complication was observed in seven (31.8%) patients. Mortality was not observed in patients during their stay at the hospital. The 5-year disease-free survival and overall survival rates were 36.8 (36%) months and 45.3 (57%) months, respectively.
Conclusions: We think that due to longer disease-free survival and overall survival, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be preferred in peritoneal carcinomatosis due to uterine cancer patients having low peritoneal carcinomatosis index scores and manageable complication rates. However, prospective randomizedtrials with a high number of cases are needed for this subject.
Keywords: cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis; uterine cancer.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603. Zhonghua Wei Chang Wai Ke Za Zhi. 2021. PMID: 34645167 Chinese.
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.Acta Gastroenterol Belg. 2022 Oct-Dec;85(4):573-579. doi: 10.51821/85.4.10811. Acta Gastroenterol Belg. 2022. PMID: 36566366
-
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.Dis Colon Rectum. 2019 Oct;62(10):1195-1203. doi: 10.1097/DCR.0000000000001456. Dis Colon Rectum. 2019. PMID: 31490828
-
Survival and complications of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5330-5348. doi: 10.26355/eurrev_202109_26640. Eur Rev Med Pharmacol Sci. 2021. PMID: 34533809
-
[Cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: a case report and review of the literature].Orv Hetil. 2006 Jan 29;147(4):147-58. Orv Hetil. 2006. PMID: 16515023 Review. Hungarian.
Cited by
-
The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy.Int J Mol Sci. 2023 Aug 2;24(15):12353. doi: 10.3390/ijms241512353. Int J Mol Sci. 2023. PMID: 37569726 Free PMC article. Review.
-
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.Cancers (Basel). 2024 Jul 25;16(15):2646. doi: 10.3390/cancers16152646. Cancers (Basel). 2024. PMID: 39123374 Free PMC article. Review.
References
-
- Lewin S.N., Herzog T.J., BarrenaMedel N.I., Deutsch I., Burke W.M., Sun X., Wright J.D. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet. Gynecol. 2010;116:1141–1149. doi: 10.1097/AOG.0b013e3181f39849. - DOI - PubMed
-
- Bakrin N., Cotte E., Sayag-Beaujard A., Raudrant D., Isaac S., Mohamed F., Gilly F.-N., Glehen O. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Carcinoma Confined to the Peritoneal Cavity. Int. J. Gynecol. Cancer. 2010;20:809–814. doi: 10.1111/IGC.0b013e3181a83f7e. - DOI - PubMed
-
- Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., Heintz A.P.M., Ngan H.Y.S., Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 2006;95:105–143. doi: 10.1016/S0020-7292(06)60031-3. - DOI - PubMed
-
- Helm C.W., Toler C.R., Martin R.S., III, Gordinier M.E., Parker L.P., Metzinger D.S., Edwards R.P. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. Int. J. Gynecol. Cancer. 2007;17:204–209. doi: 10.1111/j.1525-1438.2006.00751.x. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous